SMPD3 and metabolic dysfunction-associated steatotic liver disease: Wu et al. recently identified SMPD3 methylation as a potential biomarker distinguishing between NASH and mild fibrosis in NAFLD patients, with mild fibrosis associated with hypermethylated SMPD3.